Aortic dissection in a patient treated with anlotinib for metastatic lung squamous cell carcinoma
Anlotinib is an anti‐angiogenic drug that targets vascular endothelial growth factor receptor, platelet‐derived growth factor receptor, fibroblast growth factor receptor, c‐Kit, and other kinases and has been approved for the treatment of advanced non‐small cell lung cancer (NSCLC). As in other small‐molecule tyrosine kinase inhibitors, adverse effects such as hypertension and cardiotoxicity may be seen. However, the relationship between anlotinib and aortic dissection has not been previously reported. Here, we present a case of aortic dissection in a 58‐year‐old male patient with advanced NSCLC without history of hypertension who received anlotinib as third‐line treatment. After four courses of anlotinib treatment, he suffered a sudden onset of back pain, sweating, anxiety, and high blood pressure (180/120 mmHg) and heart rate (137 bpm). Emergency computed tomographic angiography revealed aortic dissection and thrombosis of the distal false lumen. Thereafter, the patient was administered nitroglycerin as antihypertensive treatment and he underwent stent‐graft intervention for aortic dissection. Anticoagulants and antihypertensive drugs were administered after the operation, and a moderate control of blood pressure was achieved. Thus, the adverse reactions of antolinib must be monitored and clinicians must be vigilant..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:11 |
|---|---|
| Enthalten in: |
Thoracic Cancer - 11(2020), 2, Seite 461-464 |
| Beteiligte Personen: |
Jiang, Bailing [VerfasserIn] |
|---|
| Anmerkungen: |
© 2020 China Lung Oncology Group and Wiley Publishing Asia Pty Ltd |
|---|
| Umfang: |
4 |
|---|
| doi: |
10.1111/1759-7714.13288 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
WLY013779702 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | WLY013779702 | ||
| 003 | DE-627 | ||
| 005 | 20230308022332.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230221s2020 xx |||||o 00| ||und c | ||
| 024 | 7 | |a 10.1111/1759-7714.13288 |2 doi | |
| 028 | 5 | 2 | |a TCA_TCA13288.xml |
| 035 | |a (DE-627)WLY013779702 | ||
| 035 | |a (WILEY)TCA13288 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 082 | 0 | 4 | |a 610 |q ASE |
| 100 | 1 | |a Jiang, Bailing |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Aortic dissection in a patient treated with anlotinib for metastatic lung squamous cell carcinoma |
| 264 | 1 | |c 2020 | |
| 300 | |a 4 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © 2020 China Lung Oncology Group and Wiley Publishing Asia Pty Ltd | ||
| 520 | |a Anlotinib is an anti‐angiogenic drug that targets vascular endothelial growth factor receptor, platelet‐derived growth factor receptor, fibroblast growth factor receptor, c‐Kit, and other kinases and has been approved for the treatment of advanced non‐small cell lung cancer (NSCLC). As in other small‐molecule tyrosine kinase inhibitors, adverse effects such as hypertension and cardiotoxicity may be seen. However, the relationship between anlotinib and aortic dissection has not been previously reported. Here, we present a case of aortic dissection in a 58‐year‐old male patient with advanced NSCLC without history of hypertension who received anlotinib as third‐line treatment. After four courses of anlotinib treatment, he suffered a sudden onset of back pain, sweating, anxiety, and high blood pressure (180/120 mmHg) and heart rate (137 bpm). Emergency computed tomographic angiography revealed aortic dissection and thrombosis of the distal false lumen. Thereafter, the patient was administered nitroglycerin as antihypertensive treatment and he underwent stent‐graft intervention for aortic dissection. Anticoagulants and antihypertensive drugs were administered after the operation, and a moderate control of blood pressure was achieved. Thus, the adverse reactions of antolinib must be monitored and clinicians must be vigilant. | ||
| 700 | 1 | |a Li, Junhe |4 aut | |
| 700 | 1 | |a Chen, Jun |4 aut | |
| 700 | 1 | |a Xiang, Xiaojun |4 aut | |
| 700 | 1 | |a Xiong, Jianping |4 aut | |
| 700 | 1 | |a Deng, Jun |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Thoracic Cancer |g 11(2020), 2, Seite 461-464 |w (DE-627)WLY013777327 |x 17597714 |7 nnns |
| 773 | 1 | 8 | |g volume:11 |g year:2020 |g number:2 |g pages:461-464 |g extent:4 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_WLY | ||
| 951 | |a AR | ||
| 952 | |d 11 |j 2020 |e 2 |h 461-464 |g 4 | ||